- Issuer
- F/m
- Inception Date
- Oct 30, 2024
- Region
- North America (U.S.)
- Category
- Health & Biotech Equities
- Leveraged
- 1x (No leverage)
- Index Tracked
- No Index (Active)
- Distribution Policy
- Accumulating
- Asset Class
- Equity
- Asset Class Size
- Small-Cap
- Asset Class Style
- Growth
- Assets Under Management
- $75M
Highlights
- Avg. Volume (1M)
- 7K
- Avg. Volume Value (1M)
- $324.22K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
LFSC Performance Chart
F/m Emerald Life Sciences Innovation ETF (LFSC) is up 24.4% since the beginning of the year. LFSC is currently trading at $46 per share.
Loading charts...
Compare this symbol against anything
Returns By Period
F/m Emerald Life Sciences Innovation ETF (LFSC) has returned 24.40% so far this year and 86.46% over the past 12 months.
F/m Emerald Life Sciences Innovation ETF
- 1D
- -2.42%
- 1M
- -1.28%
- 6M
- 27.81%
- YTD
- 24.40%
- 1Y
- 86.46%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 40.92%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
LFSC Monthly Returns History
Based on dividend-adjusted daily data since Oct 31, 2024, LFSC's average daily return is +0.15%, while the average monthly return is +3.04%. At this rate, an investment would double in approximately 1.9 years.
Historically, 59% of months were positive and 41% were negative. The best month was Nov 2025 with a return of +15.3%, while the worst month was Dec 2024 at -11.3%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 2 months.
On a daily basis, LFSC closed higher 56% of trading days. The best single day was Apr 9, 2025 with a return of +7.8%, while the worst single day was Apr 4, 2025 at -6.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.66% | 2.07% | -3.82% | 8.68% | 3.59% | 14.76% | 0.77% | 24.40% | |||||
| 2025 | 11.94% | -6.19% | -8.59% | 2.53% | -0.40% | 7.38% | -1.60% | 15.05% | 6.69% | 10.54% | 15.33% | -3.42% | 56.54% |
| 2024 | -0.52% | 5.95% | -11.30% | -6.51% |
Benchmark Metrics
F/m Emerald Life Sciences Innovation ETF has an annualized alpha of 24.26%, beta of 1.06, and R2 of 0.38 versus S&P 500 Index. Calculated based on daily prices since October 31, 2024.
- This ETF captured 199.45% of S&P 500 Index gains but only 83.14% of its losses - a favorable profile for investors.
- R2 of 0.38 means the benchmark explains less than half of this ETF's behavior - treat beta with caution or consider switching to a more representative benchmark.
- Alpha
- 24.26%
- Beta
- 1.06
- R²
- 0.38
- Upside Capture
- 199.45%
- Downside Capture
- 83.14%
Expense Ratio
LFSC has an expense ratio of 0.54%, placing it in the medium range.
Return for Risk
Risk / Return Rank
LFSC ranks 94 for risk / return — above 94% of ETFs peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for F/m Emerald Life Sciences Innovation ETF (LFSC) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| LFSC | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.83 | ||
| Sortino ratioReturn per unit of downside risk | +2.12 | ||
| Omega ratioGain probability vs. loss probability | 1.49 | 1.25 | +0.24 |
| Calmar ratioReturn relative to maximum drawdown | 5.45 | 2.00 | +3.45 |
| Martin ratioReturn relative to average drawdown | 15.35 | 8.49 | +6.85 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the F/m Emerald Life Sciences Innovation ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the F/m Emerald Life Sciences Innovation ETF was 29.74%, occurring on Apr 8, 2025. Recovery took 94 trading sessions.
The current F/m Emerald Life Sciences Innovation ETF drawdown is 3.85%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-29.74%Apr 2025 | 4mo 27d | 4mo 16d | 9mo 13dNov 2024 - Aug 2025 | 2025 selloff2025 |
-16.25%Mar 2026 | 3mo 19d | 1mo 29d | 5mo 18dDec 2025 - May 2026 | — |
-6.30%Jul 2026 | 10d | — | 24dJul 2026 - now | — |
-4.92%Sep 2025 | 6d | 2d | 8dSep 2025 - Sep 2025 | — |
-4.73%Nov 2025 | 3d | 4d | 7dNov 2025 - Nov 2025 | — |
Drawdown Indicators
| LFSC | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -29.74% | -56.78% | +27.04% |
Max Drawdown (1Y)Largest decline over 1 year | -16.25% | -9.10% | -7.15% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -3.85% | -1.58% | -2.27% |
Average DrawdownAverage peak-to-trough decline | -7.26% | -10.70% | +3.44% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.76% | 2.14% | +3.62% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Build a portfolio with LFSC
Add F/m Emerald Life Sciences Innovation ETF to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with LFSC